Antisense oligonucleotides containing conformationally constrained 2',4'-(N-methoxy)aminomethylene and 2',4'-aminooxymethylene and 2'-O,4'-C-aminomethylene bridged nucleoside analogues show improved potency in animal models

Journal of Medicinal Chemistry
Thazha P PrakashBalkrishen Bhat

Abstract

To identify chemistries and strategies to improve the potency of MOE second generation ASOs, we have evaluated gapmer antisense oligonucleotides containing BNAs having N-O bonds. These modifications include N-MeO-amino BNA, N-Me-aminooxy BNA, 2',4'-BNA(NC)[NMe], and 2',4'-BNA(NC) bridged nucleoside analogues. These modifications provided increased thermal stability and improved in vitro activity compared to the corresponding ASO containing the MOE modification. Additionally, ASOs containing N-MeO-amino BNA, N-Me-aminooxy BNA, and 2',4'-BNA(NC)[NMe] modifications showed improved in vivo activity (>5-fold) compared to MOE ASO. Importantly, toxicity parameters, such as AST, ALT, liver, kidney, and body weights, were found to be normal for N-MeO-amino BNA, N-Me-aminooxy BNA, and 2',4'-BNA(NC)[NMe] ASO treated animals. The data generated in these experiments suggest that N-MeO-amino BNA, N-Me-aminooxy BNA, and 2',4'-BNA(NC)[NMe] are useful modifications for applications in both antisense and other oligonucleotide based drug discovery efforts.

References

Apr 11, 1991·Nucleic Acids Research·R H AlulR L Letsinger
Jun 9, 1999·Nature Structural Biology·M TeplovaM Egli
May 11, 2000·Antisense & Nucleic Acid Drug Development·F Eckstein
Jan 19, 2002·The Journal of Organic Chemistry·Thazha P PrakashMuthiah Manoharan
Mar 28, 2002·Diabetes·Madeline ButlerBrett P Monia
Aug 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Bradley A ZinkerMichael R Jirousek
Nov 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·K Lea SewellF Andrew Dorr
Feb 27, 2003·Journal of the American Chemical Society·Andrei P Guzaev, Muthiah Manoharan
Apr 16, 2003·European Journal of Biochemistry·Jens Kurreck
Oct 23, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Richard S GearyArthur A Levin
Dec 4, 2003·Journal of Pharmaceutical Sciences·Rosie Z YuArthur A Levin
Jun 19, 2004·The Journal of Biological Chemistry·Walt F LimaStanley T Crooke
Apr 25, 2007·Nucleosides, Nucleotides & Nucleic Acids·Zhiwei WangVasulinga T Ravikumar
Mar 18, 2008·Journal of the American Chemical Society·S M Abdur RahmanTakeshi Imanishi

❮ Previous
Next ❯

Citations

Oct 5, 2010·Journal of the American Chemical Society·Punit P SethEric E Swayze
Mar 31, 2011·Future Medicinal Chemistry·Tsuyoshi YamamotoSatoshi Obika
Jan 28, 2014·Nucleic Acid Therapeutics·Motoyuki ItohSatoshi Obika
Aug 13, 2015·International Journal of Molecular Sciences·Mohube B MaepaPatrick Arbuthnot
Sep 17, 2011·Chemistry & Biodiversity·Thazha P Prakash
Sep 18, 2013·Artificial DNA, PNA & XNA·Masayasu Kuwahara, Satoshi Obika
Aug 28, 2012·Chemistry & Biology·Glen F Deleavey, Masad J Damha
Jul 20, 2016·Journal of Medicinal Chemistry·W Brad Wan, Punit P Seth
Jan 6, 2016·Chemical Communications : Chem Comm·Jiro KondoHidetaka Torigoe
Sep 27, 2018·The Journal of Clinical Investigation·Aditi ShastriAmit Verma
Oct 5, 2018·Annual Review of Pharmacology and Toxicology·C I Edvard Smith, Rula Zain
Jun 19, 2013·Current Protocols in Nucleic Acid Chemistry·Andrei P Guzaev
Jun 20, 2017·Current Protocols in Nucleic Acid Chemistry·Oleksandr PlashkevychJyoti Chattopadhyaya
Nov 9, 2016·Molecular BioSystems·Kunihiko MorihiroSatoshi Obika
Jul 29, 2016·Journal of Atherosclerosis and Thrombosis·Tsuyoshi YamamotoMariko Harada-Shiba
Oct 20, 2012·Chembiochem : a European Journal of Chemical Biology·Aiko YaharaSatoshi Obika
Jul 1, 2017·Drugs·Altaf DawoodRobert G Gish
Oct 13, 2016·Annual Review of Pharmacology and Toxicology·C Frank BennettRichard S Geary
Oct 19, 2011·Organic Letters·Kazuto MoriSatoshi Obika
Nov 9, 2011·The Journal of Organic Chemistry·Ajaya R ShresthaSatoshi Obika
Dec 7, 2018·Biochemistry·Alexandre J DebackerJonathan K Watts

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.